The real world outcomes of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST).

Piotr Rutkowski,Marcin Zietek,Bożena Cybulska-Stopa,Joanna Streb,Stanisław Głuszek,Michał Jankowski,Karolina Łopacka-Szatan,Manuela Las-Jankowska,Piotr Hudziec,Anna Klimczak,Tomasz Olesiński,T. Switaj,Hanna Koseła-Paterczyk,Elzbieta Bylina,C. Osuch

The real world outcomes of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST).

2020

Piotr Rutkowski
Marcin Zietek
Bożena Cybulska-Stopa
Joanna Streb
Stanisław Głuszek
Michał Jankowski
Karolina Łopacka-Szatan
Manuela Las-Jankowska
Piotr Hudziec
Anna Klimczak
Tomasz Olesiński
T. Switaj
Hanna Koseła-Paterczyk
Elzbieta Bylina
C. Osuch

e23524Background: The real-world data on outcomes of adjuvant therapy in high-risk gastrointestinal stromal tumors (GIST) are very limited. Methods: We have analyzed the data of 107 consecutive pat...

Keywords:

Oncology
real world outcomes
GiST
Imatinib
Internal medicine
Stromal cell
Adjuvant therapy
Pathology
in patient
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations